Stock Price & Volume | Full Chart
No headlines found.
Globe Newswire (Wed, 13-Sep 9:15 AM ET)
BioPharma Journal (Tue, 5-Sep 4:57 PM ET)
Globe Newswire (Tue, 5-Sep 8:00 AM ET)
Globe Newswire (Wed, 30-Aug 9:00 AM ET)
Globe Newswire (Mon, 21-Aug 9:00 AM ET)
Globe Newswire (Mon, 24-Jul 9:00 AM ET)
Globe Newswire (Wed, 19-Jul 9:00 AM ET)
Globe Newswire (Mon, 10-Jul 9:00 AM ET)
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. It has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
Avalon Globocare Corp. trades on the NASDAQ stock market under the symbol ALBT.
As of September 29, 2023, ALBT stock price declined to $0.80 with 30,909 million shares trading.
ALBT has a beta of -0.11, meaning it tends to be less sensitive to market movements. ALBT has a correlation of 0.00 to the broad based SPY ETF.
ALBT has a market cap of $8.70 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that ALBT belongs to (by Net Assets): VTI, VXF, ITOT.
ALBT support price is $.76 and resistance is $.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALBT stock will trade within this expected range on the day.